- Directors and Auditors
- Articles of Association
- General Meetings
- - Previous General Meetings
- Insider Trading
GenesisCare selects Dignitana as preferred scalp cooling provider for its rapidly expanding Australia medical oncology centres
Dignitana has been selected as the preferred scalp cooling provider by Australia-headquartered GenesisCare, one of the largest networks of integrated oncology care in the world. This is Dignitana’s largest single commitment for DigniCap Delta units since the next generation device launched in 2019. The DigniCap® Scalp Cooling System minimizes hair loss from chemotherapy in patients with solid tumors.
The partnership will see the roll out of DigniCap Delta systems across GenesisCare’s seven pre-existing medical oncology facilities in Australia. DigniCap systems will then be installed over the next two to three years at additional GenesisCare facilities in Australia as those locations begin to provide chemotherapy.
Over the past 12 months, GenesisCare has evaluated DigniCap Delta and selected Dignitana as the preferred provider based on:
- Improved patient outcomes
- Ease of use for clinical staff
- Single patient wraps facilitating COVID-19 protocols
“We are delighted to be partnering with Aurora BioScience and Dignitana to offer this new scalp cooling technology to help patients save their hair throughout treatment,” said Ian Maytom, GenesisCare General Manager for Medical Oncology in Australia.
“Hair loss during chemotherapy can be extremely confronting for patients, many of whom are concerned about attracting attention and having to answer questions relating to their diagnosis and treatment.”
“At GenesisCare we believe in a holistic approach to cancer care which considers both the physical and emotional needs of our patients. We share Dignitana’s commitment to minimizing the emotional burdens associated with chemotherapy and supporting the psychological health of cancer patients.”
GenesisCare is a leading oncology provider globally, with more than 5,500 highly trained physicians, healthcare professionals and support staff delivering treatments to more than 400,000 people at 440 locations in Australia, the UK, the United States and Spain.
“With this partnership DigniCap is accessible to thousands more patients who would otherwise face the prospect of losing their hair during chemotherapy,” said William Cronin, Dignitana CEO. “GenesisCare truly is a global leader in oncology and we are thrilled to be working with their experienced and innovative team who share our commitment of putting patients first.”
Paving the way for wider adoption of scalp cooling in Australia, on September 20th Cancer Australia released updated Guidance for the management of early breast cancer patients which now includes a recommendation to “Consider scalp cooling to reduce the risk of hair loss for patients receiving chemotherapy.” The Recommendation is similar to the 2019 National Comprehensive Cancer Network® (NCCN®) clinical practice guidelines for breast cancer which include scalp cooling as a Class 2A recommendation (version 1.2019).
“Demand for this important therapy is growing and together we will make scalp cooling a standard in modern cancer care,” said Darren Banks, Managing Director of Aurora BioScience, Dignitana’s longtime distribution partner and the exclusive importer and reseller of DigniCap in Australia and New Zealand. “There is no doubt that scalp cooling is now something that cancer patients want and need to improve their quality of life at a very difficult time.”
In 2019 the next generation DigniCap Delta device received clearance from the U.S. Food and Drug Administration and Australia’s Therapeutic Goods Administration. DigniCap is currently available in 40 countries worldwide.
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 02-12-2020 08:00 CET.
For More Information Contact
Melissa Bourestom, VP Corporate Communications email@example.com +1 469-518-5031
Mandy Crispin, Operations Director, Aurora BioScience +61 (0)2 9629 9546 firstname.lastname@example.org
Dignitana AB is the world leader in clinically superior scalp cooling technology. The company produces The DigniCap® Scalp Cooling System, a patented medical cooling device that offers cancer patients the ability to minimize hair loss during chemotherapy. FDA cleared since 2015, DigniCap provides continuous cooling with high efficacy, safety and patient comfort. Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. Dignitana AB is listed on Nasdaq First North Growth Market in Sweden with headquarters in Lund, Sweden and operations based in Dallas, Texas in the United States. Company subsidiaries are Dignitana, Inc. in the United States and Dignitana S.r.l. in Italy. Certified Adviser is Redeye AB, +46 8 121 576 90, email@example.com and www.redeye.se. Learn more at www.dignitana.se and www.dignicap.com.
Sydney-headquartered GenesisCare delivers treatment to people with cancer and heart disease, the two largest disease burdens globally. We’re committed to leading the change in how care is given and are currently leading or participating in more than 150 clinical trials. The organisation employs more than 5,500 highly trained physicians, healthcare professionals and support staff across Australia, Europe, and now the U.S. This follows our acquisition of major U.S. integrated oncology provider 21st Century Oncology in May 2020.
Every year GenesisCare clinical teams see more than 400,000 people at more than 440 locations. For cancer treatment, that includes more than 290 locations in the U.S., 38 locations in Australia, 14 in the UK and 21 in Spain, with more than 30 new centres under development. We also offer cardiology and sleep services at more than 80 locations across Australia. Our purpose is to design care experiences that get the best possible life outcomes. We believe that care should be focused on the individual, not the condition, and are proud of our world-class patient satisfaction ratings. For more information visit www. genesiscare.com
About Aurora BioScience
Aurora BioScience is a leading and respected medical device distribution and marketing company that provides high tech medical devices specializing in Oncology, Blood Technologies and Medical Innovations. For over 15 years they have supported healthcare providers and patients across metropolitan and regional areas of Australia, throughout New Zealand and around the Pacific Islands. With its head office located in Sydney Australia, their growing product range includes some of the world’s most innovative medical products and solutions. Aurora’s specialty medical devices are specifically chosen for its ability to assist clinicians in improving patient outcomes and to enhance a patient’s quality of Iife. For more information, please visit www.aurorabioscience.com.au